Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00787033 · ClinicalTrials.gov registry record · Phase 1
A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies
A Phase 1 study, sponsored by Verastem.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT00787033 is a Phase 1 study that has completed, run by Verastem. The registered enrollment target is 46 participants.
The verdict
NCT00787033, a Phase 1 study, has completed, sponsored by Verastem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
Phase 1 safety, pharmacokinetics, and pharmacodynamics trial of the focal adhesion kinase (FAK) inhibitor PF-04554878 in patients with advanced non-hematologic malignancies, including patients with malignancies appropriate for serial biopsy. Screening consists of medical history, physical examination ECOG performance status, blood draws, a pregnancy test for female patients of childbearing potential, a FDG-PET and tumor imaging. Treatment consists of PF-04554878 pills continued until progression of disease, unacceptable toxicity, or patient request. Evaluations for bioactivity are measured by serial FDG-PET and blood tests for biomarkers related to FAK and Pyk2 activities.
Interventions
- DRUG PF-04554878
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2008-12 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00787033
The ClinicalTrials.gov registry entry for NCT00787033 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verastem, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-04554878 is the first listed.
NCT00787033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00787033 about?
NCT00787033 is a clinical study titled "A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies". Phase 1 safety, pharmacokinetics, and pharmacodynamics trial of the focal adhesion kinase (FAK) inhibitor PF-04554878 in patients with advanced non-hematologic malignancies, including patients with malignancies appropriate for serial biopsy. Screening consists of medical history, physical examinatio...
What is the current status of trial NCT00787033?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2008-12. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00787033?
The interventions under investigation include: PF-04554878 (DRUG).
Who is sponsoring clinical trial NCT00787033?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.